Clinical Ink Selected for Multiple Ebola Clinical Studies

Clinical Ink Selected for Multiple Ebola Clinical Studies

With SureSource® clinical data is captured in real-time and monitored remotely – accelerating analysis and review of critical study data and documents

December 10, 2014 10:32 AM Eastern Standard Time

WINSTON-SALEM, N.C. & PHILADELPHIA--()--Clinical Ink, the pioneering provider of eSource solutions for clinical trials, announced today that the SureSource platform has been selected for multiple Ebola clinical studies. SureSource is unique in that the critical study data and site documents are available for real-time analysis and remote review – limiting the number of healthcare workers that will come in contact with the virus while speeding up the analysis process.

"The Ebola outbreak brings into sharp focus the need to update the clinical trial process from one that relies on pen and paper to one that leverages technological advancements like SureSource to save time and save lives," said Ed Seguine, CEO for Clinical Ink. "SureSource is uniquely positioned to change the clinical trial execution process and we are pleased to have been selected to participate in the effort to find effective treatment options for Ebola. "

Ebola trials represent a number of particularly acute challenges to the established model of conducting clinical research. At least 18 companies1 are working on preventative vaccines or drugs for Ebola and even though regulators are 'fast-tracking' review/approval processes, assessing the safety and efficacy of each therapy is hampered by the dangerous and remote conditions facing healthcare workers.

With SureSource healthcare workers enter information directly on the SureSource tablet eliminating the time consuming process of pen and paper notes, then transcription, then review, then analysis, making trends visible immediately. Data and documents are available immediately in real-time – which will enable sponsors and regulators to make decisions more quickly. October 29, 2014

About Clinical Ink

Founded in 2007, Clinical Ink is dedicated to transforming clinical development - from Start to Submit™ - by creating a completely 'paperless' clinical trial platform. Clinical Ink's SureSource platform is purpose-built to capture source data and documents electronically for sites, subjects, sponsors, and CROs. Clinical Ink maintains offices in Winston-Salem, NC and Philadelphia, PA. Additional information is available at or toll-free 1-800-301-5033.


Coltrin & Associates, for Clinical Ink
Jennifer Webb, 212-221-1616 x 111
[email protected]


Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.